| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Citi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2011-06-17 08:48:33 |
| Versijas komentārs | |
| Teksts |
JSC “Grindeks” informs that the recently unveiled
UDCA active pharmaceutical ingredient’s manufacturing unit
will increase the turnover. When a manufacturing unit of UDCA
will work at full capacity, the UDCA turnover will increase to 10
million euros a year. In its turn, after the development and
registration of the final dosage form during the next 2 - 3 years,
the turnover could rise by 10 million euros more per
year.
As announced, on 16 June in Riga, 53 Krusptils Street,
JSC “Grindeks” unveiled UDCA active pharmaceutical ingredient’s
manufacturing unit, which is one of the most significant investment
projects of “Grindeks”. Manufacturing unit’s construction was
started in 2009, after a multi-stage, long-term cooperation
agreement on regular UDCA supply was concluded with the German
pharmaceutical company “Marenis Pharma”. 6.34 million lats were
invested in the construction of the new manufacturing unit, out of
which 2.8 million lats was the co-financing by the European
Regional Development Fund (ERDF).
On
“Grindeks”
“Grindeks” is the leading pharmaceutical company in the
Baltic States. Its main fields of action are: research,
development, manufacturing and sale of original products, generics
and active pharmaceutical ingredients. “Grindeks” specializes in
the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups.
The Group consists of four subsidiary companies in
Latvia, Estonia and Russia, as well representative offices in ten
countries. Products of the company are exported to 50 countries and
its export comprises more than 95% of the total turnover. The main
markets are: Russia and other CIS countries, the Baltic States,
Germany and the Netherlands. JSC “Grindeks” shares are listed in
the Official List of “NASDAQ
OMXRiga”.
Further information on the company –
www.grindeks.lv
Further information:
Laila Klavina
Head of the Communications Department
JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: laila.klavina@grindeks.lv
Project “Creation of Ursodeoxycholic Acid manufacturing unit with the necessary infrastructure” is co-funded by the European Regional Development Fund |
| Pielikumi |
|